CLL
Conference Coverage
First-line obinutuzumab monotherapy in CLL linked to good response, reduced toxicity
NEW YORK – Obinutuzumab monotherapy effective for the first-line treatment of chronic lymphocytic leukemia.
Conference Coverage
NF-kB inhibitor IT-901 shows promise in Richter syndrome
In vitro analyses of primary leukemic cells and in vivo analyses in patient-derived xenograft models indicate NF-kB inhibition should be...
Conference Coverage
Telomere length predicts FCR response in CLL patients
NEW YORK – Telomere length reliably predicts response to fludarabine-cyclophosphamide-rituximab (FCR) treatment in patients with chronic...
Conference Coverage
Optimizing therapy in relapsed CLL: ibrutinib and beyond
CHICAGO – The efficacy of ibrutinib is durable for patients with relapsed chronic lymphocytic leukemia (CLL), and combination strategies are...
Conference Coverage
Twofer drug blocks SYK/JAK pathways in advanced NHL
MADRID – Cerdulatinib is an orally dosed agent that inhibits both the Janus kinase (JAK) 1 and 3 pathways and the spleen tyrosine kinase (SYK)...
News
FDA approves rituximab + hyaluronidase human for FL, DLBCL, and CLL
Approval provides patients a subcutaneous route for rituximab, significantly reducing the administration time.
Conference Coverage
Lenalidomide consolidation linked to extended overall survival in non-del(11q) CLL
CHICAGO – Lenalidomide consolidation therapy was associated with an extended survival plateau for patients with non-del(11q) chronic lymphocytic...
Conference Coverage
Sequential triple therapy produces high response rates in CLL
“Sequential triple-T” (tailored and targeted treatment) aimed at complete eradication of MRD looks promising for CLL.
Conference Coverage
Hitting BTK, PI3K pays off in B-cell malignancies
Umbralisib, a second-generation PI3K inhibitor, appears to have a better safety profile than the first-in-class agent idelalisib.
Conference Coverage
NOTCH1 mutation predicts reduced ofatumumab efficacy in CLL
NEW YORK – Consider CLL patients with NOTCH1 gene mutation for chemotherapy “without type1 CD20 antibodies or a treatment with novel compounds.”...
Conference Coverage
iFCG achieves high MRD-negative remission in untreated CLL
NEW YORK – Could a three-course regimen for CLL have a positive affect on treatment?